SecBot SecBot
SECBOTREPLAY Home › Report › ANVS

ANVS · Annovis Bio filed a preliminary 424B5 for an underwritten offering of…

Annovis Bio, Inc. · 424B5 filed May 19, 2026 at 17:25 ET

At the news

BEARISHIMPACT 7/10

424B5 filed May 19, 2026 at 17:25 ET

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing disclosed. The company has a going concern, cash of $14.2M (insufficient for 12 months), and an accumulated deficit of $181.3M. The offering will be highly dilutive to existing shareholders.

  • Preliminary prospectus for offering of common stock and warrants (nine-tenths warrant per share, six-year term).
  • Cash and cash equivalents of $14.2M as of March 31, 2026, insufficient to fund operations for the next 12 months.
  • Accumulated deficit of $181.3M; going concern uncertainty noted.
  • Phase 3 Alzheimer's trial enrollment 85% complete; cash expected to last only until Q4 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access